
|Videos|June 30, 2017
Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets
Author(s)Sara M. Tolaney, MD, MPH
This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses an early trial studying the CDK4/6 inhibitor abemaciclib for the treatment of brain metastases in patients with hormone receptor (HR)-positive HER2-negative breast cancer.
Tolaney presented the study results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma
2
Unmet Needs, Combination Therapies, and the Future of CAR T Consolidation in MCL
3
Tandem 2026: Key Advances in Cellular Therapy and Transplantation
4
The Need for a Shift Toward Early Detection in Pancreatic Cancer
5










































